NetraAI Study Accepted for Publication in npj Digital Medicine, Part of the Nature Portfolio

TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI powered precision analytics in the pharmaceutical industry, today announced that its peer-reviewed paper, “Explainable AI-Driven Precision Clinical Trial Enrichment: Demonstration of the NetraAI Platform with a Phase II Depression Trial,” has been accepted for publication in np ...